Physician profile

David Holst

Orthopaedic Surgery · Midlothian, VA

NPI 1952660342

$10,731.21

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$4,050.00
Travel and Lodging$1,109.38
Food and Beverage$440.07

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Depuy Synthes Products, INC. $5,360.71 2022-2024
Medical Device Business Services, INC. $4,034.38 2023-2024 Attune
Depuy Synthes Sales INC. $896.05 2019-2023 Attune, Velys, Sigma
Ethicon US, LLC $139.57 2024 Vistaseal, Stratafix, Ethicon
Zimmer Biomet Holdings, INC. $122.07 2019
Uoc USA INC $98.05 2019
Stryker Corporation $80.38 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

David Holst

$10,731.21

in general payments reported 2019-2025

Years
2019-2024
Top company
Depuy Synthes Products, INC.

https://glasscript.com/doctor/4029075/david-holst

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.